Goldman Sachs’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-1,191,359
| Closed | -$4.88M | – | 6924 |
|
|
2022
Q1 | $4.88M | Buy |
1,191,359
+51,656
| +5% | +$187K | ﹤0.01% | 3375 |
|
|
2021
Q4 | $4.07M | Buy |
1,139,703
+713,905
| +168% | +$2.5M | ﹤0.01% | 3609 |
|
|
2021
Q3 | $1.55M | Buy |
425,798
+55,818
| +15% | +$226K | ﹤0.01% | 4406 |
|
|
2021
Q2 | $1.61M | Buy |
369,980
+103,472
| +39% | +$422K | ﹤0.01% | 4389 |
|
|
2021
Q1 | $1.09M | Sell |
266,508
-519,450
| -66% | -$2.25M | ﹤0.01% | 4536 |
|
|
2020
Q4 | $3.14M | Sell |
785,958
-174,073
| -18% | -$563K | ﹤0.01% | 3385 |
|
|
2020
Q3 | $2.59M | Buy |
960,031
+129,722
| +16% | +$359K | ﹤0.01% | 3380 |
|
|
2020
Q2 | $2.28M | Buy |
830,309
+247,842
| +43% | +$692K | ﹤0.01% | 3366 |
|
|
2020
Q1 | $1.37M | Sell |
582,467
-499,013
| -46% | -$1.7M | ﹤0.01% | 3545 |
|
|
2019
Q4 | $5.08M | Buy |
1,081,480
+734,783
| +212% | +$3.01M | ﹤0.01% | 2949 |
|
|
2019
Q3 | $1.16M | Buy |
346,697
+176,112
| +103% | +$580K | ﹤0.01% | 3927 |
|
|
2019
Q2 | $562K | Sell |
170,585
-167,100
| -49% | -$483K | ﹤0.01% | 4334 |
|
|
2019
Q1 | $1.02M | Buy |
337,685
+203,492
| +152% | +$659K | ﹤0.01% | 4041 |
|
|
2018
Q4 | $365K | Buy |
134,193
+32,740
| +32% | +$108K | ﹤0.01% | 4541 |
|
|
2018
Q3 | $341K | Sell |
101,453
-5,590
| -5% | -$17.3K | ﹤0.01% | 4643 |
|
|
2018
Q2 | $277K | Sell |
107,043
-16,468
| -13% | -$41K | ﹤0.01% | 4823 |
|
|
2018
Q1 | $271K | Sell |
123,511
-5,959
| -5% | -$13.4K | ﹤0.01% | 4835 |
|
|
2017
Q4 | $257K | Sell |
129,470
-205,037
| -61% | -$446K | ﹤0.01% | 5273 |
|
|
2017
Q3 | $1.08M | Sell |
334,507
-45,135
| -12% | -$139K | ﹤0.01% | 4507 |
|
|
2017
Q2 | $1.22M | Sell |
379,642
-197,022
| -34% | -$558K | ﹤0.01% | 4273 |
|
|
2017
Q1 | $1.64M | Buy |
576,664
+445,009
| +338% | +$1.07M | ﹤0.01% | 3944 |
|
|
2016
Q4 | $307K | Sell |
131,655
-174,847
| -57% | -$333K | ﹤0.01% | 5466 |
|
|
2016
Q3 | $515K | Buy |
306,502
+8,587
| +3% | +$10.5K | ﹤0.01% | 5022 |
|
|
2016
Q2 | $313K | Buy |
297,915
+275,007
| +1,200% | +$266K | ﹤0.01% | 5291 |
|
|
2016
Q1 | $20K | Sell |
22,908
-97,151
| -81% | -$94K | ﹤0.01% | 6749 |
|
|
2015
Q4 | $145K | Sell |
120,059
-28,476
| -19% | -$39.6K | ﹤0.01% | 5934 |
|
|
2015
Q3 | $253K | Buy |
148,535
+77,967
| +110% | +$153K | ﹤0.01% | 5772 |
|
|
2015
Q2 | $147K | Buy |
70,568
+5,973
| +9% | +$14.5K | ﹤0.01% | 6383 |
|
|
2015
Q1 | $175K | Sell |
64,595
-35,087
| -35% | -$89K | ﹤0.01% | 6113 |
|
|
2014
Q4 | $256K | Buy |
99,682
+4,028
| +4% | +$9.05K | ﹤0.01% | 5945 |
|
|
2014
Q3 | $175K | Buy |
95,654
+3,348
| +4% | +$7.3K | ﹤0.01% | 6263 |
|
|
2014
Q2 | $246K | Sell |
92,306
-6,236
| -6% | -$18.8K | ﹤0.01% | 6036 |
|
|
2014
Q1 | $345K | Sell |
98,542
-32,436
| -25% | -$144K | ﹤0.01% | 5616 |
|
|
2013
Q4 | $586K | Buy |
130,978
+46,151
| +54% | +$188K | ﹤0.01% | 5181 |
|
|
2013
Q3 | $344K | Buy |
84,827
+15,550
| +22% | +$67.9K | ﹤0.01% | 5465 |
|
|
2013
Q2 | $288K | Buy |
+69,277
| New | +$268K | ﹤0.01% | 5346 |
|
Other funds holding ATRS
Goldman Sachs's ATRS Position: Q2 2022 in Review
Goldman Sachs sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 1,191,359 shares — an estimated $4.88M sold.
Goldman Sachs first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $5.08M in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Goldman Sachs reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Goldman Sachs sold 1,191,359 Antares Pharma, Inc. shares in Q2 2022, an estimated $4.88M.
- Goldman Sachs first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Goldman Sachs's Antares Pharma, Inc. position peaked at $5.08M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.